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Background: The optimal revascularization strategy for left main (LM) disease in the
era of drug-eluting stents has become controversial. Consensus guidelines recommend
coronary artery bypass graft surgery for the treatment of significant de novo LM
stenosis; however, the recommendation for unprotected left main coronary artery
(ULMCA) percutaneous coronary intervention has recently received a Class IIb
indication. This analysis will focus on outcomes of LM patients (pts) in the SYNTAX
trial at 4 years.
Methods: SYNTAX randomized pts with de novo 3 vessel (3VD) and/or LM disease
to PCI with TAXUS Express stents or CABG if suitable for equivalent
revascularization using either treatment. Analysis of this unprotected LM cohort was
prespecified and sufficiently powered.
Results: Three-year MACCE and the composite of death/stroke/MI were similar in
ULMCA- PCI and CABG-treated pts (Table). Stroke was significantly increased in
the CABG group and repeat revascularization was increased in the PCI arm at 3 years
(Table). MACCE was similar between groups in pts with lower SYNTAX Scores (0-
32: 23.2% vs 20.5%, p=0.45) but significantly increased in PCI pts with high scores
(≥33: 21.2% vs 37.3%, p=0.003).
Conclusion: At 3-years, no difference in MACCE was found between groups. There
was an advantage of PCI in stroke; a benefit in the need for reintervention was still
found in CABG. SYNTAX and other recent studies of LM disease suggest that in some
pts, PCI using drug-eluting stents may be as effective but less invasive than CABG.
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Background: The Nile PAX® dedicated drug-eluting stent (Minvasys SAS, France)
is a novel technology designed for percutaneous treatment of coronary bifurcation
lesions with a provisional approach that incorporates: 1. a cobalt-chromium alloy
designed to optimize scaffold of the bifurcation carina with maintenance of side branch
(SB) access without need for rewiring (Nile CroCo® platform, Minvasys SAS, France);
2. a non-polymeric coating (PAX) technology; and 3. a potent antiproliferative agent
(paclitaxel).
Methods: From Dec/08 to Mar/09, a total of 101 pts with single bifurcation lesion
were prospectively enrolled in this non-randomized, multicenter (10 sites in
Europe/South America) study. Lesion criteria were vessel size 2.5-3.5mm in the parent
vessel (PV) and 2.0-3.0mm in the SB, and lesion length <14mm in the PV.
Results: LAD/Dg was the most prevalent location (75%), and 60% had significant
involvement of both branches. In the procedure, PV was predilated in 97%; the study
stent was successfully attempted and implanted in 99%. Overall, 25% of SB received
an additional stent; and 94% of lesions had final kissing-balloon inflation.
Angiographic success (residual stenosis <50%, final TIMI 3 flow, and absence of
dissection) was achieved in 98%. There was only 1 major adverse cardiac event during
hospitalization, which was adjudicated as a non-Q myocardial infarction during
hospitalization, and no additional adverse events were reported up to 30 days. At 9
months, binary restenosis (primary endpoint) was 13.8% in the PV and 12.6% in the
SB, and clinical outcomes included 8.4% clinically-driven target lesion
revascularization (TLR) and no occurence of death or stent thrombosis.
Conclusion: The novel Nile PAX dedicated bifurcation polymer-free technology
demonstrated excellent performance in the treatment of complex bifurcation lesions,
including high procedural success and no events from discharge to 30 days FU. Up to
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Concomitant Clopidogrel and Statin Use and Risk of Major Adverse
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Background: The clopidogrel-statin interaction has not been examined using time-
varying drug exposure ascertainment. We examined whether statin use modified the
association between clopidogrel use and major adverse cardiovascular events (MACE)
after coronary stent implantation.
Methods: We conducted this population-based cohort study in Western Denmark
(population: 3 million) using medical databases. We identified all 13,001 patients with
coronary stent implantation between 2002 and 2005 and their comorbidities. During
12-month follow-up, we tracked use of clopidogrel and statins and the rate of MACE.
We used Cox regression to compute hazard ratios controlling for potential confounders.
Results: The rate of MACE per 1000 person years was 104 for concomitant clopidogrel
and statin use, 129 for clopidogrel without statin use, 107 for statin without clopidogrel
use, and 449 for no use of either drug. The adjusted hazard ratio comparing clopidogrel
use with non-use was 0.68 (95% confidence interval: 0.58-0.80) among statin users
and 0.34 (95% confidence interval: 0.29-0.40) among statin non-users, yielding an
interaction effect (i.e., relative rate increase) of 1.99 (95% confidence interval: 1.61-
2.47). The adjusted hazard ratio for MACE comparing statin use with non-use was
0.97 (95% confidence interval: 0.83-1.13) among clopidogrel users and 0.49 (95%
confidence interval: 0.42-0.57) among clopidogrel non-users.
Conclusion: Clopidogrel and statin use was each associated with a substantially
reduced rate of MACE within 12 months after coronary stent implantation. Although
we observed an interaction between use of clopidogrel and statins, statin use vs. nonuse
was not associated with an increased rate of MACE in patients using clopidogrel after
coronary stent implantation.
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Short-acting, Reversible Antiplatelet Therapy For Urgent Surgery Early After
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Background: Between 4 and 8% of pts need to undergo surgery in the first year after
DES deployment. Dual antiplatelet therapy (DAPT) is associated with a 25% incidence
of severe perioperative bleeding and is not protective against MACE, particularly in
the early months after implantation. We hypothesized that i.v. short acting perioperative
antiplatelet therapy using tirofiban during clopidogrel withdrawal would reduce the
risk of D+MI+ST with no excess in bleeding.We used a Simon two-stage design to
test the hypothesis that this approach would reduce the incidence of D+MI+ST from
30% to 5% (N=21)
Methods: Inclusion criteria:pts at high-risk for surgical bleeding within 12 months of
DES implantation.Exclusion criteria: allergy to tirofiban (tir),stroke< 30
days,intracranial disease,trombocytopenia. At day -5 to surgery (surg) stop clopidogrel.
At day -3 start tir (0,4 mg/kg/min over 30’,followed by 0,1mg/kg/min). At -4h to surg
stop tir. At +4h from surg resume tir. Resume clopidogrel as soon as oral administration
is possible. Stop tir after 1 day.ASA continued throughout.Primary EP: the composite
of death,MI,ST,haemostatic reoperation. Secondary EP: TIMI major bleeding.
Results: 56 pts enrolled in the bridge- therapy study for urgent surgery (surg) 4 days-
12 months from DES implantation (median 3 months).In 19 pts cardiovascular surg,
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in 37 non cardiovascular (urinary tract 7 pts, gastrointestinal 18 pts,mixed surg 12).
Primart EP :0 (97,5% CI 6,4%). Bleeding events : 2 major, according TIMI criteria
(gastrointesinal surg), 2 minor, trasfusion in 11 pts. Severe thrombocitopenia (platelet
count < 20.000): 1 pt.
Conclusion: Based on the results of our prospective study we propose that a “bridge
strategy” using short-acting i.v. antiplatelet agents confers protection against
perioperative CV events that goes beyond the prevention of stent thrombosis, without
increasing the risk of bleeding, in pts in DAPT, planned for urgent surgery < = 12
months after DES implantation.
TCT-53
Death and Acute Myocardial Infarction Associated with Stopping Clopidogrel
After Saphenous Vein Graft Percutaneous Coronary Intervention
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Background: It remains unknown whether high-risk cohorts undergoing percutaneous
coronary intervention (PCI) are at an increased risk of adverse events after clopidogrel
cessation. We assessed the rates of adverse events after stopping clopidogrel treatment
in patients who had undergone saphenous vein graft (SVG) PCI.
Methods: We identified patients undergoing SVG PCI between 2000-2009 in an
integrated pre-paid health care plan. Clopidogrel utilization was ascertained from
pharmacy records. The date of the prescription and quantity of tablets dispensed were
recorded for every clopidogrel prescription filled by the patient post-PCI. A
multivariate Cox regression model was constructed to obtain risk-adjusted
instantaneous incidence rates using kernel hazard functions. The following covariates
were included in the model: age, gender, comorbidities, clopidogrel duration and non-
compliance, and use of concomitant medications (beta blockers, statins, and others).
Results: Among 603 patients who underwent SVG PCI during the study period, 403
were event free at the time of clopidogrel cessation and comprised the study cohort.
Risk-adjusted instantaneous incidence rates for death or myocardial infarction after
stopping clopidogrel treatment are shown in the figure. The risk of an adverse event
appears to be greatest early after cessation of clopidogrel therapy, regardless of stent
type.
Conclusion: A clustering of events was observed in the near-term after clopidogrel
cessation in patients treated with either drug-eluting or bare metal stents. Additional
studies are needed to confirm these findings and determine the responsible
mechanisms.
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The impact of High Residual Platelet Reactivity After Clopidogrel Loading on
Long-Term Clinical Outcome of Patients with Acute Coronary Syndromes
Receiving an Invasive Treatment. The RECLOSE 2-ACS trial
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Background: Context High residual platelet reactivity (HRPR) on clopidogrel has
been associated with high risk of ischemic events after percutaneous coronary
intervention (PCI). To test the hypothesis that HRPR after clopidogrel loading would
be an independent prognostic marker of risk of long-term thrombotic events in patients
with acute coronary syndrome (ACS) receiving an invasive treatment and
antithrombotic treatment adjusted according to the results of platelet function tests.
Methods: Prospective, observational, referral center cohort study of 1789 consecutive
ACS patients undergoing PCI from April 2005 to April 2009, and for whom platelet
reactivity was prospectively assessed by light transmittance aggregometry. Patients
with HRPR by ADP test (≥ 70%) received an increased dose of clopidogrel (from 150
mg/daily to 300 mg/daily), or shifted to ticlopidine (500mg/daily to 1000 mg/daily),
under ADP test guidance (clinicaltrials.gov Identifier: NCT01231035). The primary
end point was the composite of cardiac death, myocardial infarction, any urgent
coronary revascularization, and stroke at 2-year follow-up. Secondary end points were
stent thrombosis, and each component of the primary end point.
Results: The primary end point rate was 14.6% in the HRPR group and 8.7% in the
low residual platelet reactivity group (p = 0.003). Stent thrombosis rate was higher in
the HRPR group as compared to the low residual platelet reactivity group (6.1% vs
2.9%, p = 0.001). By multivariable analysis, HRPR was an independent predictor of
the primary end point (HR1.49, 95% CI 1.08-2.05, p = 0.015) and of cardiac mortality
(HR 1.81, 95% CI 1.18-2.76, p = 0.006).
Conclusion: HRPR is a strong predictor of short- and long-term ischemic events,
including stent thrombosis. Antiplatelet therapy using increased maintenance dose of
clopidogrel or ticlopidine, has no impact on clinical outcome.
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Is clopidogrel enough for STEMI patients with cardiogenic shock?
Klaus Tiroch1, 2, Dirk Sibbing2, Isabelle Bernlochner2, Melchior Seyfarth1, Adnan
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Background: ST-elevation myocardial-infarction (STEMI) patients show an
attenuated platelet inhibition to clopidogrel 600 mg-loading dose. It could be
hypothesized that STEMI patients with cardiogenic shock may even respond worse to
standard clopidogrel loading. Thus, the aim of this study was to compare platelet
inhibition in STEMI patients with and without cardiogenic shock after clopidogrel
loading.
Methods: In this study, 237 consecutive STEMI patients (207 without cardiogenic
shock and 30 with cardiogenic shock) were evaluated regarding their platelet inhibition
using the Multiplate analyzer. Cardiogenic shock was defined as hemodynamic
instability with need for catecholamines or intubated patients with clopidogrel 600mg-
loading over nasogastric tube. We further assessed the number of primary clopidogrel
low-responders (defined as >468 AU*min) and their response to an additional
clopidogrel 600 mg-loading, and if necessary, to a further prasugrel 60 mg-loading.
Results: Platelet inhibition after clopidogrel 600 mg-loading was less effective for
STEMI patients with cardiogenic shock (median 643 AU*min, interquartile range 448-
1009) compared to those without cardiogenic shock (median 492 AU*min, interquartile
range 222-822) (P=0.04). Platelet inhibition after prasugrel 60 mg-loading was highly
effective in primary clopidogrel low responders.
Conclusion: Clopidogrel-induced platelet inhibition was significantly less effective
for STEMI patients with cardiogenic shock compared to those without cardiogenic
shock. Prasugrel was effective in primary clopidogrel low responders and may
represent a better choice for STEMI patients with cardiogenic shock leading to highly
activated platelets and impaired resorption and metabolization.
TCT-56
Impact of Major Bleeding on Long term Mortality in patients with and without
Anemia Undergoing Percutaneous Coronary Intervention with Bivalirudin
Shyam Poludasu1, Usman Baber1, Avery E Clark2, Rebecca Pinnelas3, George
Dangas1, Roxana Mehran1, Annapoorna S Kini1, Samin K Sharma1
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Background: Bleeding complications after percutaneous coronary intervention (PCI)
have been associated with increased mortality. These data have been derived in the
context of using Bivalirudin (BIV) versus heparin + GPIIb/IIIa inhibitors after PCI
and especially STEMI. We studied the predictors of mortality after PCI in a population
treated exclusively with BIV and we investigated the role of anemia on clinical
outcomes.
Methods: We evaluated 11,991 patients who underwent PCI from July 2001 to May
2010 with bivalirudin as the primary antithrombotic agent. Bleeding complications
were prospectively collected and defined by the criteria used in The Harmonizing
Outcomes with Revascularization and Stents in Acute Myocardial Infarction
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